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Serum ferritin levels increase in postmenopausal women, and they are reported to be linked
to major health problems. Here, we investigated the association between serum ferritin lev-
els and insulin resistance (IR) in postmenopausal women.
Methods
A total of 6632 healthy Korean women (4357 premenopausal and 2275 postmenopausal)
who participated in the Korean National Health and Nutrition Examination Survey
(KNHANES) in 2007–2010 were enrolled in the study. Serum ferritin values were divided
into six groups for the premenopausal and postmenopausal groups. IR and obesity indices
were evaluated according to the six serum ferritin groups. Statistical analysis was carried
out using SAS software, version 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
The association between the IR indices and ferritin groups had a higher level of statistical
significance in the postmenopausal group than in the premenopausal group. In addition, for
the postmenopausal group, the estimates increased significantly in the sixth ferritin group
compared to those in the first ferritin group. However, the association between the obesity
indices and ferritin levels was not significantly different between the premenopausal and
postmenopausal groups.
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Conclusion
Elevated serum ferritin levels were associated with an increased risk of insulin resistance in
postmenopausal women.
Introduction
Iron is an important trace element that is required for transporting oxygen, oxidative phos-
phorylation, DNA biosynthesis, xenobiotic metabolism, and biological processes that involve
the transfer of electrons in the human body [1,2]. Electron transfer occurs via oxidation-reduc-
tion reactions that cause iron to fluctuate between its ferric (+3) and ferrous (+2) states [3].
This fluctuation can cause toxicity if there is an excess of “labile iron”.
Serum ferritin is the most reliable marker of iron stores in the body. As women age and go
through menopause, their bodies undergo several physiological changes, including those of
serum ferritin levels. Serum ferritin levels increase in postmenopausal women as a result of the
cessation of menstrual periods. Researchers have hypothesized that increased serum ferritin
levels, including those that are within the normal physiological range, are linked to major
health problems in postmenopausal women [4]. For example, iron is proposed to have a role in
the pathogenesis of many diseases, such as IR, diabetes mellitus (DM), infection, cardiovascular
diseases (CVD), and cancer [5].
IR is a physiological condition that is closely linked to metabolic syndrome and DM. The
incidence of IR is increasing and early diagnosis has become important to better manage and
prevent patients from developing more severe diseases. Generally, IR is diagnosed by measur-
ing fasting insulin levels or glucose tolerance tests. However, patients do not regularly take
those specific blood tests unless they have other underlying diseases or are diligent about hav-
ing regular health check-ups. Most patients visit hospitals after suffering from symptoms of IR
or developing other diseases. It is preferable to have a diagnostic marker that allows physicians
to predict and prevent IR as early as possible.
Previous studies describe a positive relationship between serum ferritin levels, which is a
marker for elevated iron stores, and IR in women and men regardless of age [6–10]. This infor-
mation combined with the fact that iron stores increase in postmenopausal women led to the
following question: do postmenopausal women with increased serum ferritin levels have a
greater risk of developing IR than premenopausal women? Therefore, we tested the hypothesis
that there is an association between serum ferritin levels and IR in postmenopausal women due
to elevated iron stores in pre- and postmenopausal women.
Subjects and Methods
Study population
The data used in this study are from the KNHANES, specifically the KNHANES IV (2007–
2009) and the KNHANES V (2010), which were conducted by the Korean Ministry of Health
andWelfare. KNHANES were each conducted using a rolling sample survey that involved a
complex, stratified, multistage, probability-cluster survey of a representative sample of the
non-institutionalized civilian population in South Korea. Individuals surveyed were randomly
selected from 2300 households in 2007, 4600 households each in 2008 and 2009, and 3840
households in 2010. The sampling units were newly selected each year and did not overlap
with previous samples. We included data from 2007–2010 in this study because insulin levels
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were not recorded from 2011. The survey consisted of three parts: a health interview survey, a
health examination survey, and a nutrition survey. All surveys were conducted by trained inter-
viewers who were not provided previous information about the survey participants. Standard
direct physical examinations were conducted in mobile examination centers. Before the survey,
the participants completed written informed consent and we received the anonymized data.
The current study was conducted according to the tenants of the Declaration of Helsinki and
was approved by the Institutional Review Board at Yonsei University Health System, Severance
Hospital (4-2015-0208).
The exclusion criteria were similar to those of our previous study [11,12] (Fig 1). From the
total of 18404 women, we initially excluded 5108 individuals who were younger than 20 years
old, pregnant, or who had undergone a hysterectomy or bilateral oophorectomy (BO). After-
wards, 2400 women who did not have anthropometric measurements of height (Ht), waist cir-
cumference (WC), and weight, or provide blood samples for ferritin, fasting glucose, or insulin
measurements were eliminated. Other exclusion criteria were aspartate aminotransferase
(AST) or alanine aminotransferase (ALT) levels>100 IU/L, hemoglobin (Hb) levels<10 g/dL,
creatinine (Cr) levels>1.4 mg/dL, white blood cell (WBC) counts>10,000/μl or<4,000/μl,
and those who suffered from CVD, liver, renal, thyroid diseases or cancer. This eliminated dis-
ease category included inflammatory diseases (i.e. hepatitis, liver cirrhosis, etc.) to eradicate the
possibility of having analytical error from serum ferritin levels being affected by inflammation.
We also did not include 17 individuals with serum ferritin levels<1 ng/mL and>500 ng/mL
because they could have ferritin-related diseases, such as hemochromatosis or sickle cell
Fig 1. Flow chart of participant enrollment.
doi:10.1371/journal.pone.0157934.g001
Serum Ferritin and Insulin Resistance in Postmenopausal KoreanWomen
PLOSONE | DOI:10.1371/journal.pone.0157934 June 23, 2016 3 / 13
disease. Ultimately, there were 6632 participants (4357 premenopausal women and 2275 post-
menopausal women) in the present study.
Variable measurements
The confounding variables included age, smoking, alcohol consumption, exercise, WBC
counts, Hb levels, Cr levels, total cholesterol levels, hormone replacement therapy (HRT), and
DM treatment. Subjects were classified as never smokers, past smokers, occasional smokers,
and current smokers (i.e., they smoked at least one cigarette per day during the previous 12
months). Alcohol consumption was categorized into six groups depending on drinking history
during the previous 12 months. Exercise levels were divided into eight groups that depended
on the number of days the subjects walked during the week. The subjects were also classified
according to whether they had any kind of HRT or DM treatment.
Anthropometric measurements, such as Ht, WC, and weight, were taken while the subjects
were wearing light clothing without shoes. Blood samples were taken in the early morning after
fasting overnight. Plasma concentrations of Hb, ferritin, insulin, fasting glucose, Cr, total cho-
lesterol, AST, and ALT levels were measured according to routine biochemical laboratory pro-
tocols. Ferritin was measured via chemiluminescent immunoassay using an ADVIA Centaur
system (Siemens, Malvern, PA, USA) through February 15, 2008 and an immunoradiometric
assay was performed with a 1470 WIZARD gamma counter (Perkin Elmer, Turku, Finland)
from February 16, 2008 until 2010. The clinical analyses were all performed at a laboratory cer-
tified by the Korean Ministry of Health and Welfare (Neodin Medical Institute).
Criteria and definitions
Menopause is defined as 12 months of amenorrhea following the final menstrual period [13].
The postmenopausal status in this study was defined as the subjects’ self-reported cessation of
menstruation for more than 1 year. We excluded those with surgical menopause (i.e., individu-
als who had a hysterectomy or BO). Serum ferritin levels higher than 500 ng/mL were used as a
marker for iron overload diseases [14,15]. Values of serum ferritin were divided into six groups
for the premenopausal and postmenopausal women. For IR indices, we used insulin, fasting
glucose levels, homeostasis model assessment IR (HOMA-IR), and obesity indices, including
BMI25 kg/m2, WC85 cm, and waist-to-height ratio (WC/Ht0.51). HOMA-IR was cal-
culated as follows: HOMA-IR = fasting glucose × insulin/405 mg/dL.
Statistical analysis
Data are expressed as means ± standard deviation for continuous variables and in percentages
(%) for categorical variables. All IR indices, including obesity indices, were compared accord-
ing to ferritin groups using one-way analysis of variance (ANOVA) and a Chi-square test. A
trend test was applied to compare the continuous variables (i.e., insulin, fasting glucose levels,
and HOMA-IR) according to ferritin groups. In order to compare IR indices according to ferri-
tin groups after adjustment for confounding variables, multiple linear logistic regression and
multiple linear regression were used to analyze the subjects. The covariates for the adjusted cal-
culation were as described above in the ‘variable measurements’ subsection. Data analysis was
carried out using SAS software, version 9.2 (SAS Institute Inc., Cary, NC, USA). We considered
a p-value of<0.05 statistically significant.
Results
Baseline clinical and laboratory characteristics of the total study population according to ferri-
tin groups are described in Tables 1 and 2. The abnormal values of BMI, WC, andWC/Ht were
Serum Ferritin and Insulin Resistance in Postmenopausal KoreanWomen
PLOSONE | DOI:10.1371/journal.pone.0157934 June 23, 2016 4 / 13
significantly associated with increasing ferritin levels in postmenopausal women. Although all
IR indices did not show significantly increasing trend according to the ferritin levels, each ferri-
tin group had significantly different values of IR indices in postmenopausal women.
The subjects were divided into two groups, 4357 premenopausal and 2275 postmenopausal
women, which were again categorized into six groups according to serum ferritin levels. Model
1 was adjusted for age only, and model 2 was adjusted for all the covariates. Both models were
analyzed with multiple linear logistic regression. Tables 3, 4 and 5 and Fig 2 show the compari-
son of adjusted odds ratios (ORs) of BMI, WC, andWC/Ht by serum ferritin levels between
the two groups. The association between the obesity indices and ferritin levels was not signifi-
cantly different between the premenopausal and postmenopausal groups. However, postmeno-
pausal women in both model 1 and 2 had significantly higher ORs in ferritin level 6 than in
ferritin level 1 (BMI; p = 0.0011 (model 1), p = 0.0229 (model 2), WC; p<0.0001 (model 1),
p = 0.0007 (model 2), and WC/Ht; p<0.0001 (model 1), p = 0.0163 (model 2). For premeno-
pausal women, all model 1 statistics showed higher ORs in ferritin level 6 than in ferritin level
1 (BMI; p = 0.0407, WC; p = 0.0001, and WC/Ht; p = 0.0008).
Odds ratio estimates for BMI, WC, and WC/Ht after adjusting with confounders in post-
menopausal women increase as serum ferritin levels increase. However, the numbers did not
show clear trends in premenopausal women. (PreM; Premenopause, PostM; Postmenopause)
Tables 6, 7 and 8 and Fig 3 describe the comparison of the estimated regression coefficient
for insulin, fasting glucose levels, and HOMA-IR by serum ferritin groups between the pre-
menopausal and postmenopausal groups. The associations between all three indices and the
Table 1. Baseline characteristics of premenopausal women according to serum ferritin groups.
1 (n = 727)F
(n = 7
2 (n = 726)
9.57<F17.32
3 (n = 727)
17.32<F25.86
4 (n = 725)
25.86<F36.62
5 (n = 727)
36.62<F52.93
6 (n = 725)
F>52.93
p-value† p-value‡
Ferritin (ng/mL) 6.2±2.05 13.42±2.26 21.37±2.47 31.14±3.18 44.02±4.6 78.02±29.19
Age 37.19±8.19 35.75±8.23 35.64±8.4 35.72±8.27 36.09±8.16 35.91±8.72 0.0033* 0.0011*
Ht (cm) 158.61±5.83 159.24±5.78 159.63±5.34 159.43±5.37 159.1±5.35 159.17±5.34 0.0130* 0.0018*
BMI (kg/m2) 22.43±3.38 22.28±3.47 22.58±3.55 22.37±3.8 22.49±3.51 22.9±3.84 0.0205* 0.8424
WC (cm) 75.41±8.6 74.9±8.73 76±9.15 75.14±9.01 75.65±8.88 77.57±10.2 <.0001* 0.8470
WC/Ht 0.476±0.057 0.471±0.056 0.477±0.059 0.472±0.058 0.476±0.058 0.488±0.065 <.0001* 0.4737
Fasting glucose (mg/dl) 91.59±17.1 89.74±11.63 89.88±13.92 89.81±10.43 91.7±17.75 93.88±25.62 <.0001* 0.0633
Insulin (μIU/mL) 9.94±4.04 9.57±4.14 9.7±5.18 9.37±4.18 9.77±8.11 9.74±3.98 0.3901 0.0611
HOMA-IR (mg/dl) 2.26±1.04 2.15±1.11 2.18±1.36 2.1±1.09 2.25±2.26 2.28±1.18 0.0897 0.0581
WBC (Thous/μl) 5.72±1.14 5.89±1.25 5.81±1.26 5.92±1.25 5.99±1.25 6.11±1.31 <.0001* 0.0128*
Hb (g/dl) 12.03±0.996 12.99±0.796 13.1±0.814 13.18±0.768 13.24±0.802 13.32±0.866 <.0001* <.0001*
Cr (mg/dl) 0.741±0.105 0.743±0.115 0.734±0.109 0.734±0.111 0.728±0.104 0.73±0.109 0.0657 0.0996
Total cholesterol (mg/dl) 181.18±31.35 177.27±30.18 174.63±28.68 176.55±30.76 176.46±31.71 179.76±34.3 0.0007* 0.0014*
AST (IU/L) 17.34±4.54 17.46±4.89 17.68±5.27 17.79±5.12 18.24±6.15 19.75±7.63 <.0001* 0.0943
ALT (IU/L) 13.94±6.43 14.3±7.11 15.03±8.84 15.18±7.82 16.44±9.7 19.03±12.84 <.0001* 0.0030*
BMI <25 576(79.23) 586(80.72) 564(77.58) 571(78.76) 576(79.23) 546(75.31) 0.1974 0.0733
25 151(20.77) 140(19.28) 163(22.42) 154(21.24) 151(20.77) 179(24.69)
WC <85 624(85.83) 633(87.19) 617(84.87) 625(86.21) 624(85.83) 572(78.9) 0.0001* 0.0008*
85 103(14.17) 93(12.81) 110(15.13) 100(13.79) 103(14.17) 153(21.1)
WC/Ht <0.51 535(73.59) 563(77.55) 543(74.69) 549(75.72) 537(73.87) 489(67.45) 0.0005* 0.0029*
0.51 192(26.41) 163(22.45) 184(25.31) 176(24.28) 190(26.13) 236(32.55)
# F = Ferritin, WC = Waist circumference, Ht = height
p-value†: Chi-square test, ANOVA
p-value‡: Trend test
* indicates statistically signiﬁcant values (p<0.05)
doi:10.1371/journal.pone.0157934.t001
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ferritin groups had a higher level of significance in the postmenopausal group (insulin,
p = 0.0005 (model 1), p = 0.0008 (model 2); fasting glucose, p = 0.0277 (model 1), p = 0.0511
(model 2); HOMA-IR, p = 0.0002 (model 1), p = 0.0015 (model 2)). In addition, the postmeno-
pausal group’s estimates increased significantly in the sixth ferritin group compared to those in
the first group (insulin, p<0.0001; fasting glucose, p<0.0001; HOMA-IR, p<0.0001). Even
after adjusting for all the covariates (i.e., age, alcohol consumption, smoking, exercise, WBC,
Hb, Cr, total cholesterol, HRT, and DM treatment), serum ferritin levels were independently
associated with insulin, fasting glucose levels, and HOMA-IR in the postmenopausal group
(insulin, p = 0.0042; fasting glucose, p = 0.0013; HOMA-IR, p = 0.0046).
The graphs describe the least squares (LS) means of insulin, fasting glucose, and HOMA-IR
according to serum ferritin groups after adjusting with confounders. The LS means according
to insulin levels in premenopausal women were 10.573, 9.794, 9.968, 9.605, 10.007, and 9.741
in the order of increasing ferritin levels. Those of postmenopausal women were 9.842, 9.845,
9.593, 9.910, 10.038, and 11.129. The LS means according to fasting glucose levels in premeno-
pausal women were 129.196, 127.132, 127.293, 126.886, 128.041, and 129.624. Those of post-
menopausal women were 115.327, 115.048, 114.952, 117.039, 117.506, and 119.687. Lastly, the
LS means according to HOMA-IR in premenopausal women were 3.328, 3.104, 3.151, 3.050,
3.189, and 3.143. Those of postmenopausal women were 2.865, 2.806, 2.760, 2.866, 2.915, and
3.287. Compared to the first ferritin group, all three graphs showed increased numbers in the
sixth ferritin group of postmenopausal women, indicating increased risk of IR. (PreM; Preme-
nopause, PostM; Postmenopause)
Table 2. Baseline characteristics of postmenopausal women according to serum ferritin groups.
1 (n = 380) 2 (n = 379) 3 (n = 379) 4 (n = 379) 5 (n = 379) 6 (n = 379) p-value† p-value‡
F29.92 29.92<F43.9 43.9<F56 56<F72.73 72.73<F98.21 F>98.21
Ferritin (ng/mL) 19.7±7.03 37.61±3.91 49.86±3.5 64.4±4.92 84.25±7.12 144.24±55.04
Age 62.35±9.51 62.32±8.94 61.64±9.2 62.61±9.44 63.6±9.44 65.13±9.65 <.0001* 0.9667
Ht (cm) 152.1±6.46 153.13±6.38 153.27±5.92 153.18±6.3 152.49±5.84 152.49±6.15 0.0432* 0.0171*
BMI (kg/m2) 23±3.42 23.31±3.43 23.2±2.98 23.38±3.41 23.51±3.4 23.93±3.64 0.0053* 0.1847
WC (cm) 78.92±9.01 80.56±8.93 80.14±8.5 81.37±8.69 81.75±8.95 83.62±9.21 <.0001* 0.0007*
WC/Ht 0.52±0.062 0.527±0.059 0.523±0.057 0.532±0.058 0.537±0.06 0.549±0.065 <0001* 0.0167*
Fasting glucose (mg/dl) 95.39±17.13 95.99±19.4 95.8±17.62 98.35±24.92 100.1±22.89 103.8±29.21 <.0001* 0.0902
Insulin (μIU/mL) 9.22±9.4 9.36±4.59 9.05±3.89 9.44±4.02 9.84±5.57 10.99±6.72 <.0001* 0.8064
HOMA-IR (mg/dl) 2.25±3.25 2.25±1.32 2.19±1.3 2.32±1.27 2.49±1.83 2.93±2.75 <.0001* 0.7501
WBC (Thous/μl) 5.69±1.2 5.68±1.21 5.73±1.23 5.74±1.16 5.9±1.29 6.02±1.39 0.0004* 0.4570
Hb (g/dl) 12.79±0.979 13±0.82 13.18±0.838 13.13±0.912 13.26±0.936 13.36±0.917 <.0001* <0001*
Cr (mg/dl) 0.75±0.132 0.741±0.121 0.733±0.121 0.738±0.123 0.739±0.127 0.749±0.133 0.3934 0.1405
Total cholesterol (mg/dl) 201.76±34.43 202.61±33.57 204.06±34.86 205.73±37.02 205.18±33.44 207.29±36.3 0.2617 0.0967
AST (IU/L) 21.92±6.52 21.68±6.12 21.76±6.49 22.31±6.41 22.89±6.76 24.81±9.81 <.0001* 0.4437
ALT (IU/L) 17.44±7.91 17.74±7.81 18.29±8.57 19.85±9.55 20.16±10.36 22.51±12.17 <.0001* 0.0004*
BMI <25 280(73.68) 261(68.87) 279(73.61) 253(66.75) 258(68.07) 238(62.8) 0.0083* 0.0014*
25 100(26.32) 118(31.13) 100(26.39) 126(33.25) 121(31.93) 141(37.2)
WC <85 285(75) 258(68.07) 274(72.3) 252(66.49) 248(65.44) 221(58.31) <.0001* <.0001*
85 95(25) 121(31.93) 105(27.7) 127(33.51) 131(34.56) 158(41.69)
WC/Ht <0.51 166(43.68) 157(41.42) 162(42.74) 142(37.47) 122(32.19) 105(27.7) <.0001* <.0001*
0.51 214(56.32) 222(58.58) 217(57.26) 237(62.53) 257(67.81) 274(72.3)
# F = Ferritin, WC = Waist circumference, Ht = height
p-value†: Chi-square test, ANOVA
p-value‡: Trend test
* indicates statistically signiﬁcant values (p<0.05)
doi:10.1371/journal.pone.0157934.t002
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Discussion
In this cross-sectional study, we analyzed the associations between serum ferritin levels and
various IR-related indices and revealed that elevated serum ferritin levels are strongly associ-
ated with increased risk of IR, especially in postmenopausal women. These associations were
also independent of several confounders.
Several previous studies describe associations between serum ferritin levels and IR, and
there were conflicting results regarding the two genders. Park et al. reported an increasing risk
of IR in proportion to the serum ferritin levels of Korean men during a 5-year follow-up period
that was independent of other confounding factors, such as age, BMI, smoking status, and
hypertension [16]. A Taiwanese study indicated that the relationship between serum ferritin
Table 3. Adjusted odds ratios (95% confidence interval) for BMI (25) by serum ferritin groups.
Premenopause Postmenopause p-value
OR(95% CI); p-value OR(95% CI); p-value
Model 1 0.2331
Ferritin level 1 1 1
Ferritin level 2 0.947(0.731–1.226); 0.6773 1.266(0.923–1.735); 0.1429
Ferritin level 3 1.150(0.894–1.478); 0.2770 1.001(0.725–1.383); 0.9950
Ferritin level 4 1.070(0.830–1.379); 0.6005 1.396(1.021–1.908); 0.0366
Ferritin level 5 1.030(0.799–1.329); 0.8182 1.319(0.963–1.807); 0.0844
Ferritin level 6 1.295(1.011–1.659); 0.0407 1.676(1.229–2.285); 0.0011
Model 2 0.3929
Ferritin level 1 1 1
Ferritin level 2 0.920(0.690–1.225); 0.5673 1.177(0.844–1.642); 0.3368
Ferritin level 3 1.146(0.860–1.528); 0.3513 0.961(0.683–1.351); 0.8174
Ferritin level 4 1.077(0.806–1.440); 0.6146 1.238(0.885–1.733); 0.2124
Ferritin level 5 0.996(0.742–1.337); 0.9799 1.214(0.869–1.698); 0.2560
Ferritin level 6 1.182(0.884–1.580); 0.2592 1.470(1.055–2.050); 0.0229
doi:10.1371/journal.pone.0157934.t003
Table 4. Adjusted odds ratios (95% confidence interval) for WC (85 cm) by serum ferritin groups.
Premenopause Postmenopause p-value
OR(95% CI); p-value OR(95% CI); p-value
Model 1 0.1713
Ferritin level 1 1 1
Ferritin level 2 0.950(0.700–1.287); 0.7385 1.408(1.025–1.934); 0.0345
Ferritin level 3 1.160(0.864–1.556); 0.3229 1.158(0.838–1.601); 0.3743
Ferritin level 4 1.036(0.768–1.398); 0.8148 1.509(1.101–2.069); 0.0106
Ferritin level 5 1.053(0.782–1.418); 0.7338 1.566(1.144–2.146); 0.0052
Ferritin level 6 1.728(1.309–2.281); 0.0001 2.09(1.532–2.85); <.0001
Model 2 0.1713
Ferritin level 1 1 1
Ferritin level 2 0.840(0.599–1.179); 0.3133 1.326(0.950–1.851); 0.0975
Ferritin level 3 1.102(0.788–1.540); 0.5709 1.079(0.767–1.519); 0.6613
Ferritin level 4 0.888(0.631–1.252); 0.4989 1.285(0.915–1.804); 0.1481
Ferritin level 5 0.876(0.620–1.237); 0.4525 1.414(1.011–1.976); 0.0427
Ferritin level 6 1.221(0.876–1.703); 0.2386 1.776(1.275–2.475); 0.0007
doi:10.1371/journal.pone.0157934.t004
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and IR is present in non-diabetic women but not in non-diabetic men [6]. On the other hand,
Kim et al. reported that increased serum ferritin levels are associated with IR, type 2 DM,
impaired fasting glucose, and metabolic syndrome in men but only with impaired fasting glu-
cose in women [7]. Furthermore, a Japanese study described serum ferritin is associated with
markers of IR in Japanese men but not in women [17]. These differences may be due to differ-
ent study designs with different study populations and adjusting confounders. Although these
studies do not agree, we can still consider serum ferritin levels to reflect the development of IR
and that there are differences between the genders. Further studies will be needed to clarify the
gender differences.
Table 5. Adjusted odds ratios (95% confidence interval) for WC/Ht (0.51) by serum ferritin groups
Premenopause Postmenopause p-value
OR(95% CI); p-value OR(95% CI); p-value
Model 1 0.3212
Ferritin level 1 1 1
Ferritin level 2 0.883(0.690–1.131); 0.3261 1.099(0.821–1.470); 0.5261
Ferritin level 3 1.049(0.823–1.337); 0.7001 1.064(0.796–1.423); 0.6744
Ferritin level 4 0.985(0.772–1.257); 0.9037 1.291(0.962–1.732); 0.0884
Ferritin level 5 1.069(0.840–1.360); 0.5900 1.584(1.175–2.137); 0.0026
Ferritin level 6 1.496(1.182–1.892); 0.0008 1.875(1.380–2.548); <.0001
Model 2 0.3554
Ferritin level 1 1 1
Ferritin level 2 0.788(0.598–1.039); 0.0917 1.012(0.742–1.380); 0.9400
Ferritin level 3 0.964(0.730–1.273); 0.7973 0.988(0.724–1.349); 0.9408
Ferritin level 4 0.860(0.649–1.138); 0.2906 1.186(0.864–1.629); 0.2919
Ferritin level 5 0.905(0.683–1.199); 0.4879 1.404(1.018–1.935); 0.0383
Ferritin level 6 1.102(0.833–1.456); 0.4971 1.498(1.077–2.083); 0.0163
BMI = body mass index, CI = conﬁdence interval, OR = odds ratio, WC = Waist circumference, Ht = height
Model 1 & 2: Multiple linear logistic regression
Model 1 was adjusted for age
Model 2 was adjusted for age + covariates (alcohol consumption, smoking status, exercise levels, WBC, Hb, Cr, total cholesterol, HRT, and DM
treatment)
doi:10.1371/journal.pone.0157934.t005
Fig 2. Odds ratio estimates for obesity indices according to serum ferritin groups after adjusting with confounders.
doi:10.1371/journal.pone.0157934.g002
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This study only included women and compared the results between premenopausal and
postmenopausal women. Postmenopausal women had higher levels of serum ferritin as a result
of cessation of menstruation. Obesity and IR indices also increased proportionately to ferritin
levels. The results for the obesity indices in the premenopausal group were less clear after
adjusting covariates. Guglielmi et al. reported that ferritin concentrations were associated with
cholesterol and AST levels in premenopausal women[18]. Consequently, adjusting those covar-
iates might have affected our results.
There are several possible explanations for the relationship between serum ferritin levels
and IR. First, several studies have reported that increased iron storage in hepatocytes results in
abnormal glucose metabolism [19–21]. Iron-mediated tissue damage is proposed to be initiated
by iron-induced oxidant stress [22,23]. Mitochondria are the targets of iron-mediated damage,
Table 6. Estimated regression coefficient for insulin by serum ferritin groups.
Premenopause Postmenopause p-value
Estimate(SE); p-value Estimate(SE); p-value
Model 1 0.0005
Ferritin level 1 0 0
Ferritin level 2 -0.407(0.271); 0.1322 0.144(0.437); 0.7411
Ferritin level 3 -0.285(0.271); 0.2920 -0.167(0.437); 0.702
Ferritin level 4 -0.609(0.271); 0.0244 0.216(0.437); 0.6202
Ferritin level 5 -0.201(0.270); 0.4571 0.615(0.437); 0.1597
Ferritin level 6 -0.231(0.271); 0.3933 1.754(0.438); <.0001
Model 2 0.0008
Ferritin level 1 0 0
Ferritin level 2 -0.778(0.291); 0.0075 0.003(0.439); 0.9941
Ferritin level 3 -0.604(0.297); 0.0421 -0.249(0.443); 0.5743
Ferritin level 4 -0.968(0.299); 0.0012 0.068(0.446); 0.8781
Ferritin level 5 -0.566(0.301); 0.0605 0.196(0.446); 0.6600
Ferritin level 6 -0.832(0.304); 0.0062 1.287(0.449); 0.0042
doi:10.1371/journal.pone.0157934.t006
Table 7. Estimated regression coefficient for fasting glucose by serum ferritin groups.
Premenopause Postmenopause p-value
Estimate(SE); p-value Estimate(SE); p-value
Model 1 0.0277
Ferritin level 1 0 0
Ferritin level 2 -1.363(0.873); 0.1183 0.605(1.615); 0.7080
Ferritin level 3 -1.188(0.873); 0.1733 0.515(1.615); 0.7496
Ferritin level 4 -1.286(0.873); 0.1407 2.916(1.615); 0.0711
Ferritin level 5 0.480(0.872); 0.5823 4.521(1.616); 0.0052
Ferritin level 6 2.722(0.873); 0.0018 7.994(1.620); <.0001
Model 2 0.0511
Ferritin level 1 0 0
Ferritin level 2 -2.063(0.809); 0.0108 -0.279(1.325); 0.8333
Ferritin level 3 -1.903(0.827); 0.0215 -0.375(1.335); 0.7790
Ferritin level 4 -2.309(0.832); 0.0055 1.712(1.345); 0.2033
Ferritin level 5 -1.155(0.838); 0.1685 2.179(1.344); 0.1052
Ferritin level 6 0.428(0.845); 0.6124 4.360(1.355); 0.0013
doi:10.1371/journal.pone.0157934.t007
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and iron may be preferentially toxic to cells with high mitochondrial activity [24], such as
hepatocytes and pancreatic beta cells. The loss of mitochondrial function leads to developing
metabolic syndrome [25]. Therefore, iron-induced oxidative stress combined with mitochon-
drial defects may be a triggering factor for metabolic disorders, such as insulin resistance.
Second, IR is currently thought to be an inflammatory process. It has been associated with
inflammatory factors such as tumor necrosis factor-α and interleukin-6 (IL-6) from adipocytes
[26–28]. Serum ferritin is pro-inflammatory, similar to IL-6, which is also correlated with IR
[28,29]. Therefore, ferritin and IR may be related to each other via the inflammatory process.
Third, lipid peroxidation is suggested to be involved in IR development and it can be induced
by iron’s catalytic effects [30,31]. Additionally, iron itself can form highly reactive free radicals
that may also disrupt glucose metabolism and cause IR [32,33].
Table 8. Estimated regression coefficient for HOMA-IR by serum ferritin groups.
Premenopause Postmenopause p-value
Estimate(SE); p-value Estimate(SE); p-value
Model 1 0.0002
Ferritin level 1 0 0
Ferritin level 2 -0.109(0.074); 0.1406 0.001(0.153); 0.9956
Ferritin level 3 -0.073(0.074); 0.3227 -0.056(0.153); 0.7126
Ferritin level 4 -0.153(0.074); 0.0375 0.070(0.153); 0.6463
Ferritin level 5 -0.006(0.074); 0.9371 0.228(0.153); 0.1363
Ferritin level 6 0.027(0.074); 0.7117 0.655(0.153); <.0001
Model 2 0.0015
Ferritin level 1 0 0
Ferritin level 2 -0.225(0.079); 0.0043 -0.059(0.145); 0.6853
Ferritin level 3 -0.177(0.080); 0.0274 -0.105(0.146); 0.4742
Ferritin level 4 -0.279(0.081); 0.0006 0.001(0.148); 0.9945
Ferritin level 5 -0.139(0.081); 0.0879 0.050(0.147); 0.7344
Ferritin level 6 -0.185(0.082); 0.0241 0.422(0.149); 0.0046
HOMA-IR = homeostasis model assessment insulin resistance
Models 1 & 2: multiple linear logistic regression
Model 1 was adjusted for age
Model 2 was adjusted for age + covariates (i.e., alcohol consumption, smoking status, exercise levels, WBC, Hb, Cr, total cholesterol, HRT, and DM
treatment)
doi:10.1371/journal.pone.0157934.t008
Fig 3. Least squaremeans for insulin resistance indices according to serum ferritin groups after adjusting with confounders.
doi:10.1371/journal.pone.0157934.g003
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There are some limitations to this study. First, due to the cross-sectional study design, the
causality between ferritin and IR is difficult to prove. This study only aimed to show the possi-
ble relationship between ferritin and IR, not the mechanism of how ferritin may have affected
the development of IR. Second, additional iron markers, such as hepcidin and transferrin con-
centration/saturation measurements, would have helped differentiate the iron status of the
study population. Third, the serum ferritin levels were only tested once for each participant.
These levels may have been affected by the participants’ nutritional and health status. It would
have been more accurate to measure the ferritin levels more than once with certain time inter-
vals to calculate mean values. Although we did exclude participants who had high WBC levels
(indicating inflammatory status), AST, ALT, and liver disease, we did not include the specific
nutritional status of the study population with regards to iron consumption.
Despite these limitations, there are strong points in this study. First, to our knowledge, this
is the first study comparing the association between serum ferritin levels and IR in premeno-
pausal and postmenopausal women using a large Asian study population (6632 participants).
The large sample number allowed us to achieve statistically significant test results. Second,
because the data was from a national survey of the common civilian population in South Korea
(i.e., not just hospital patients), the risk of having selection bias was reduced. Third, this was
the first study to focus on premenopausal and postmenopausal women’s ferritin and IR status.
It is interesting to note, from the study results, that postmenopausal women had a higher risk
of IR than premenopausal women. The possible explanation for this is that the estrogen pro-
duction declines at menopause, and this decline increases the levels of oxidative stress [34],
which may explain the association between ferritin and insulin resistance.
In conclusion, elevated serum ferritin levels were associated with an increased risk of IR in
postmenopausal women. Prospective or longitudinal studies will be needed to further clarify
the causality between ferritin levels and IR.
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